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Abstract 
Objective: To develop a new score system for patients with prostate specific antigen (PSA) ranging from 4 to 20 ng/
mL to improve the accuracy of prostate cancer (PCa) detection, and to evaluate it with receiver operating characteris-
tic curve.
Methods: A total of 797 patients (208 with prostate cancer) with total PSA 4–20 ng/mL who had undergone tran-
srectal ultrasound (TRUS)-guided 12 + 1-core prostate biopsy during Sept. 2009–Jan. 2013 were retrospectively evalu-
ated in the study. Age, PSA, fPSA, PV, f/T, PSAD, DRE findings and ultrasound findings were considered as predictive 
factors and tested by logistic regression. Predictors with P < 0.05 were selected to develop a new score system.
Results: Age, PSA, PV, f/T, DRE findings, and hypoechoic in ultrasound were selected in our new score system. The 
risk of PCa increased with the score. From 0 to 6, the risk was 2.0, 8.4, 13.9, 33.5, 63.8, 75.0 and 100.0 % respectively. 
Area under curve (AUC) of our new score system was 0.804, which was significantly higher than The Prostate Cancer 
Risk Calculator by Stichting Wetenschappelijk Onderzoek Prostaatkanker (SWOP) (0.720, P = 0.002).
Conclusions: We developed a new simple score system for patients with PSA ranging from 4 to 20 ng/mL to 
improve the accuracy of PCa detection.
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Background
Prostate specific antigen (PSA) is widely used for the 
screening of prostate cancer in recent years. How-
ever, an increasing level of PSA can also represent the 
occurrence of benign prostate hyperplasia (BPH) and 
prostatitis, which questioned the specificity of PSA 
in predicting prostate cancer (Catalona et  al. 1995). 
Although the region of PSA levels from 4 to 10 ng/mL is 
defined as a “gray zone” according to the traditional con-
cepts, the prostate cancer detection rate of the patients 
with PSA levels of 10–20  ng/mL is not superior to the 
patients whose PSA levels in the “gray zone” conspicu-
ously. The incidence rate was 25 % or less in the region of 
PSA from 4 to 20 ng/mL (Tang et al. 2013; Chavan et al. 
2009). The rate of the patients with the PSA level in range 
of 4–20  ng/mL in the initial examination in clinic has 
been increase since the examination of PSA level was a 
routine physical examination. Clearly, there is an urgent 
need to develop a new system for improving the detec-
tion rate and reducing unnecessary prostate biopsies in 
the region of PSA levels from 4 to 20 ng/mL.
Methods
Ethics statement
This study was approved by the institutional review 
board of the First Affiliated Hospital of Nanjing Medical 
University. Written informed consent was obtained from 
all patients with regard to the storage of their informa-
tion for the purpose of research. All research procedures 
were conducted in accordance with the Declaration of 
Helsinki.
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Characteristics and methods
Our study included 797 patients, who had an elevated 
PSA level ranging from 4 to 20  ng/mL and had under-
gone a transrectal ultrasound (TRUS)-guided prostate 
biopsy from September 2009 to January 2013 at the 
First Affiliated Hospital of Nanjing Medical University, 
China. All the patients envolved in our study are Chi-
nese men. Detail patient information, including age, PSA, 
free PSA (fPSA), digital rectal examination (DRE) find-
ings and other clinical information were recorded before 
prostate biopsy. The information of patients’ PSA levels 
were provided by laboratory of the First Affiliated Hos-
pital of Nanjing Medical University, they used a single 
validated assay to assess PSA levels. An ellipsoid formula 
(PI/6 × lateral × anteroposterior × superoinferior diam-
eters) was used to calculate the prostate volume (PV) of 
every patient in this study by means of ultrasonoscopy, 
and detailed observation were carried out regarding 
microcalcifications and hypoechoic lesions. PSA density 
(PSAD) was defined as the ratio of PSA to PV. The free/
total PSA ratio (f/T) was calculated by dividing the level 
of fPSA present by the total level of PSA.
We used Philips Envisor C Ultrasound Machine to 
localized the position and used Bard Maxcore Dispos-
able Biopsy Instrument MC1820 to collected the tis-
sue of prostate. The TRUS-guided prostate biopsy from 
September 2009 to January 2013 were performed by 
experienced urologists in the First Affiliated Hospital of 
Nanjing Medical University. Routine examination includ-
ing blood, liver and kidney function and coagulation was 
taken by the patients before the prostate biopsy.
Statistical analysis
Statistical analysis was performed using SPSS 18.0 soft-
ware. Differences between data of the patients were ana-
lyzed using the t test for continuous variables and the 
Chi square test for categorical variables. We used multi-
ple logistic regression analysis with a backward elimina-
tion selection procedure to select potential predictors. 
One score was given when the positive factors more 
than the median score. 100 patients from a total of 797 
patients with total PSA 4–20 ng/mL who had undergone 
TRUS-guided 12 +  1-core prostate biopsy during Sept. 
2009–Jan. 2013 the First Affiliated Hospital of Nanjing 
Medical University were randomly selected with random 
number table for assessment of effectiveness of the new 
score system and The Prostate Cancer Risk Calculator by 
Stichting Wetenschappelijk Onderzoek Prostaatkanker 
(SWOP), which is an initiative of the Department of 
Urology of the Erasmus MC, the University and Medi-
cal Centre of Rotterdam, in The Netherlands. Erasmus 
MC is one of eight European centers taking part in the 
world’s largest study of screening for prostate cancer, the 
European Randomized Study of Screening for Prostate 
Cancer (ERSPC). We used a receiver-operating charac-
teristic (ROC) curve to assess the effectiveness of the new 
score system and The Prostate Cancer Risk Calculator by 
SWOP Finally, Z-test was used to compare the difference 
of the area under the curve. We considered statistical sig-
nificant when P value <0.05.
Results
In this study, 208 (27  %) of 797 patients had positive 
biopsy results. The characteristic details of the patients 
in the study cohort are indicated in Table  1. The mean 
ages of patients in the PCa group and the non-PCa group 
were 70.6 ± 6.8 and 66.9 ± 8.7 years; P < 0.01. Moreover, 
other statistical differences including PSA (P  <  0.001), 
fPSA (P < 0.001), PSAD (P < 0.001), f/TPSA (P < 0.001) 
DRE findings (P < 0.001) and hypoechoic under transrec-
tal ultrasound findings (P  <  0.001) were found between 
the PCa group and non-PCa group. However, there is 
no significant statistical difference in microcalcifications 
(P = 0.262). Univariate analysis indicated that age, PSA, 
fPSA, f/T, PV, PSAD, abnormal DRE and the rate of ultra-
sonic hypoechoic mass in patients with a positive initial 
prostate biopsy were different from patients with an ini-
tial negative biopsy. Age, PSA, fPSA, t/T, PV, PSAD, DRE 
findings and ultrasonic hypoechoic mass were included 
in logistic analysis on multivariate analysis. The categori-
cal variables were valuated before analysis. We valuated 
abnormal and no significant abnormal DRE findings as 
1 and 0 score; valuated hypo echoic mass and no signifi-
cant hypoechoic mass in TURS as 1 and 0 score; valuated 
positive and negative prostate biopsy finding as 1 and 0 
score. All the other independent variable were included 
in the logistic analysis as continuous variables. After a 
backward elimination selection procedure, six predic-
tors indicated significant differences (Age, PSA, t/T, PV, 
DRE findings and ultrasonic hypoechoic mass in TURS) 
suggested that these parameters were potential predic-
tors for initial prostate biopsy (Table  2). According to 
the result of the logistic analysis, the new system model 
was created including the significantly potential predic-
tors such as age, PSA, f/T, PV, DRE findings and hypo 
echoic mass in TURS. The section point was defined as 
the overall median of the predictors. Positive factors such 
as age > 69, PSA > 9.3 was valuated as 1 score; while neg-
ative factors such as PV < 37.1, f/T < 0.14 was valuated 
1 score. Additionally, abnormal DRE findings and hypo 
echoic mass in TURS was also valuated as 1 score. The 
positive rate of new score system is shown in Table 3.
Receiver operating characteristic (ROC) was used to 
evaluated the accuracy of PCa detection in the new score 
system (Fig. 1). A notable rise of the area under the curve 
(AUC) of the ROC for the new score system (0.804) was 
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observed by using the Z-test in this study when com-
pared with The Prostate Cancer Risk Calculator by 
SWOP (0.72, P = 0.002).
Table 1 Characteristics of the patient cohort in the first stage of the study
Values are mean ± SD and number
Student’s t test for age, PSA, fPSA, PV, PSAD and f/t distributions between Pca and Non-Pca groups
Two-sided χ2-test or Fish’s exact test for DRE findings, hypoechoic, and microcalcification between Pca and Non-Pca groups
DRE digital rectal examination, PSA prostate-specific antigen, fPSA free prostate-specific antigen, PSAD prostate-specific antigen density, PV prostate volume, neg 
negative, pos positive
a Hypoechoic masses and microcalcifications were observed using ultrasound
Variables Non-PCa Group (%) PCa Group (%) Overall median P
Number of patients 589 208
Age 66.9 ± 8.3 70.6 ± 6.8 69 <0.001
PSA 9.8 ± 4.0 11.2 ± 4.2 9.3 <0.001
fPSA 1.6 ± 1.2 1.3 ± 0.8 1.3 0.003
PV 46.2 ± 23.6 33.8 ± 13.7 37.1 <0.001
PSAD 0.25 ± 0.17 0.38 ± 0.20 0.24 <0.001
f/T 0.17 ± 0.11 0.12 ± 0.06 0.14 <0.001
DRE findings <0.001
Neg 545 78.6 148 21.4
Pos 44 32.3 60 57.7
Hypoechoica <0.001
Neg 468 78.8 126 21.2
Pos 121 59.6 82 40.4
Microcalcificationa 0.262
Neg 415 74.6 141 25.4
Pos 174 72.2 67 27.8
Table 2 Multivariate analysis of the predictors of prostate 
cancer
a Reference category was negative
Variables B SE OR 95 % CI P
Intercept 2.996 0.949 0.002
PV −0.048 0.007 0.953 0.940–0.966 <0.001
Age 0.085 0.014 1.088 1.060–1.118 <0.001
Abnormal DREa 1.611 0.257 0.2 0.121–0.331 <0.001
Hypoechoica 0.871 0.205 0.419 0.280–0.626 <0.001
f/t −7.148 1.638 0.001 0–0.02 <0.001
PSA 0.094 0.024 1.099 1.048–1.152 <0.001
Table 3 The positive prostate biopsy rate of new score sys-
tem
Neg negative, Pos positive
Score Neg Pos (%)
N N
0 48 1 2
1 152 14 8.4
2 216 35 13.9
3 129 65 33.5
4 34 60 63.8
5 10 30 75
6 0 3 100
Fig. 1 ROC of our new score system and SWOP. The AUC of these 
predictors were 0.804 and 0.720
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Discussion
PSA is a conventional clinical screening parameter. How-
ever, the increase of PSA can also been observed in vari-
ous situation such as benign prostatic hypertrophy (BPH), 
inflammation and prostate cancer (Littrup et  al. 1994). 
Screening of PSA was also questioned by some scholars 
because although it increase the detection rate, the mortal-
ity is still not reduce and also bring the problem of over-
diagnosis and overtreatment (Peres 2013). The number of 
patients with PSA level ranging from 4 to 20 ng/mL in the 
initial clinic examination is increasing since the PSA level 
was been an event of the routine examination in some med-
ical center, China. A large amount of unnecessary prostate 
biopsy will be performed if we still insist on PSA > 4 as the 
biopsy indication (Wolf et al. 2010). Considering of the low 
specificity of the screening of PSA, some other upgraded 
predictors such as PSAD, f/T and The Prostate Cancer Risk 
Calculator by SWOP were introduced. However, most of 
these parameters have involved from PSA, therefore mak-
ing them provincial (Vickers et al. 2009).
Previous research has shown that predictive mod-
els which based on clinical laboratory and ultrasound 
parameters, DRE findings can improve the accuracy of 
prostate cancer detection to a various degrees (Carlson 
et al. 1998; Eastham et al. 1999; Potter et al. 2001). Unfor-
tunately, score systems based other races usually unsuit-
able for Chinese men. Furthermore, it is hard to use the 
score model in clinic because it remains controversial 
(Park et  al. 2011). Thus, it is obvious that particularly 
designed for the patients with PSA level ranging from 4 
to 20  ng/mL can gain further insights. In this study we 
develop a new score system to improve the accuracy of 
prostate cancer in PSA from 4 to 20 ng/mL.
10–14 cores biopsy has gained widespread acceptance 
in the initial examination (Scattoni et al. 2007; Ukimura 
et al. 2013). We used 12 + 1 cores biopsy with ultrasound 
and got high accuracy of PCa detection, which guarantee 
the dependability of our new score system.
The positive rate of patients had positive biopsy results 
in this study was more than 50 % when score >3, which 
means patients with 0 and 1 score had a low positive rate 
of biopsy (<10 %). Encourage patients with 0 and 1 score 
to receive prostate biopsy may lead to overdiagnosis and 
overtreatment.
ROC curve is widely used to evaluate clinic diagnosis 
index. AUC shows a positive correlation with the value of 
diagnosis index. AUC of our new score system was 0.790, 
which was significantly higher than The Prostate Cancer 
Risk Calculator by SWOP (0.720, P = 0.002) (Fig. 1). The 
accuracy of PCa detection of the new score system is sig-
nificantly higher than single parameter.
Prostate biopsy belongs to invasive examination and 
has some risks including bleeding and infection. PCa is 
a common malignant disease in elderly people, who are 
also suffering from the threaten of some chronic disease 
such as hypertension, diabetes and coronary artery dis-
ease. Previous studies have demonstrated that the accu-
racy of PCa detection of patients with PSA level ranging 
from 4 to 20 ng/mL is low. Thus, elderly patients should 
undergo biopsies depended on their physical conditions. 
A new score system was developed based on our study. 
According to the system, patients with 0–1 score should 
closely monitored for PSA; patients with 2 score should 
consider to biopsy according to physical examinations; 
patients with score ≥3 should undergo biopsy actively. 
The other advantage of the new score system is that pre-
dictors such as PSA, PV, age, DRE finding, hypoechoic 
mass and f/T are routine clinical examination events. 
It is convenient to use new score system on outpatients 
instead of complex formulas.
Conclusions
In conclusion, we developed a new score system to 
improve the accuracy of prostate cancer detection in PSA 
4–20 ng/mL. A reasonable prostate biopsy strategy based 
on the new score system was demonstrated to reduce the 
unnecessary prostate biopsies and increase the detection 
rate of PCa.
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